Aurora kinase-IN-1

• UNSPSC Description:

  Aurora kinase-IN-1 (Compound 9) is a potent inhibitor of aurora kinase. Aurora kinase-IN-1 upregulates the expression of G1 cell cycle inhibitory proteins including p21 and p27, and G1 progressive cyclin D1, and downregulates G1-to-S progressive cyclins, resulting in cell cycle arrest at the G1/S boundary. Aurora kinase-IN-1 also induces apoptosis. Aurora kinase-IN-1 is a lead compound for chemotherapeutic agents[1].

• Target Antigen:

  Apoptosis; Aurora Kinase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/aurora-kinase-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCOC(/C(C1=O)=C/NC2=NC(C3=CC=C(C(OC)=C3)OC)=CC(C4=CC=C(C=C4)Br)=N2)OC5=C1C=C(Br)C=C5

• Molecular Weight:

  667.34

• References & Citations:

  [1]Shin SY, et al. Design, synthesis, and biological activities of 3-((4,6-diphenylpyrimidin-2-ylamino)methylene)-2,3-dihydrochromen-4-ones [published online ahead of print, 2022 Jan 20]. Bioorg Chem. 2022;120:105634.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported